Does a cardiovascular event change adherence to statin treatment in patients with type 2 diabetes? A matched cohort design

F. M. de Vries, P. Denig, S. Vegter, H. J. Bos, M. J. Postma, E. Hak

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)
6 Downloads (Pure)



To be effective, adherence to statin treatment is essential. We assessed the effect of an apparent first cardiovascular event on statin adherence rates in type 2 diabetes patients.

Research design and methods:

A matched cohort study was conducted among type 2 diabetes patients initiating statin treatment for primary prevention in the Groningen University IADB. nl pharmacy database. Patients who had a drug-treated cardiovascular event (index date) after statin initiation were matched to a reference patient without such an event with similar gender, age at statin initiation, initiation date, follow-up period and adherence level before the event. Adherence rates were measured as percentages of days covered (PDC), and shifts in adherence levels (non-adherent/partially adherent/fully adherent) and rates around the event were evaluated.


We could match 375 of the 855 eligible index patients to a reference patient. Index patients had on average a PDC of 81% after the index date; reference patients had a PDC of 71% (p


Medication proxies were used, which could have caused misclassification. Furthermore, a substantial group of index patients could not be matched to a reference patient due to small ranges in matching criteria.


The occurrence of a drug-treated cardiovascular event appeared to avert the declining statin adherence rate observed in diabetes patients without such an event. On the other hand, one in five patients became less adherent after the event, indicating that there are still important benefits to achieve.

Original languageEnglish
Pages (from-to)595-602
Number of pages8
JournalCurrent Medical Research and Opinion
Issue number4
Publication statusPublished - Apr-2015


  • Adherence
  • Cardiovascular diseases
  • Diabetes mellitus
  • Hydroxymethylglutaryl
  • CoA reductase inhibitors

Cite this